SEATTLE, Nov. 28, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that the Company strengthened its leadership team with the appointment of Monique M. Greer as Senior Vice President, Investor Relations and Corporate Communications, and Marc C. Chamberlain, M.D., as Medical Director. Ms. Greer will be a member of the Company's executive committee and will report to Scott D. Myers, Chief Executive Officer of Cascadian Therapeutics. Ms. Greer will have responsibility for external communications, including investor relations, media and digital communications, and advocacy relations. Dr. Chamberlain, a neuro-oncologist, will serve as Medical Director reporting to Dr. Luke Walker, Vice President, Clinical Development. Dr. Chamberlain will be focused on applying his expertise in understanding and treating brain tumors and metastatic diseases in the Central Nervous System (CNS) to Cascadian's lead late-stage development program evaluating tucatinib, formerly known as ONT-380, in HER2-positive metastatic breast cancer. "We are pleased to have these talented leaders join Cascadian at this important time in our corporate development," said Scott D. Myers, Chief Executive Officer. "We believe that their proven leadership and skill sets will benefit us as we continue to advance tucatinib, our lead program for the treatment of patients with HER2-positive breast cancer in patients with or without brain metastases, through late-stage clinical development and towards commercialization."Monique M. GreerMs. Greer, a veteran biopharmaceutical executive, joins Cascadian Therapeutics with over 20 years of experience driving communications strategies and initiatives. She has played an active role in several successful financing rounds and helped launch multiple drugs in the U.S. and Europe. Ms. Greer was most recently Senior Vice President of Corporate Communications and Investor Relations at CTI BioPharma Corp., where she led the company's corporate, investor and product communications. Ms. Greer also served in similar functions at Allos Therapeutics, Inc. (acquired by Spectrum Pharmaceuticals); WCG, a global communications agency; Dendreon Corporation and Heska Corporation.